TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX) Feb 26, 2026 01:30PM
BioCryst Pharma (BCRX) Tops Q4 EPS by 108c; offers outlook Feb 26, 2026 07:58AM
Evercore ISI Resumes BioCryst Pharma (BCRX) at Outperform, Adds to Core SMID list Feb 18, 2026 08:18AM
BioCryst Pharma (BCRX) Reiterated at Overweight by Cantor Fitzgerald Jan 13, 2026 07:13AM
BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens: A Strong Quarter Jan 13, 2026 04:05AM
View Older Stories

Jan 12, 2026 07:04AM BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%
Jan 9, 2026 07:16AM BioCryst raises ORLADEYO drug price by 9% starting January 2026
Dec 16, 2025 06:54AM BioCryst Pharma (BCRX) PT Raised to $32 at H.C. Wainwright
Dec 15, 2025 04:03AM BioCryst Pharma's (BCRX) Orladeyo Pediatric Approval Will Drive Sales - Citizens
Dec 12, 2025 10:16AM TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)
Dec 3, 2025 07:01AM BioCryst receives antitrust clearance for Astria acquisition
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 6, 2025 08:00AM BioCryst presents pediatric HAE data at medical conference
Nov 5, 2025 04:53AM BioCryst Pharma (BCRX) PT Lowered to $25 at Citizens After Missing 3Q Sales Consensus
Nov 4, 2025 09:12AM Cantor Fitzgerald Reiterates Overweight Rating on BioCryst Pharma (BCRX)
Nov 3, 2025 07:03AM BioCryst Pharma (BCRX) Tops Q3 EPS by 11c ; Offers Guidance
Oct 15, 2025 07:24AM H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)
Oct 15, 2025 07:07AM BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition
Oct 15, 2025 04:39AM TD Cowen Resumes BioCryst Pharma (BCRX) at Buy, PT $30
Oct 15, 2025 04:23AM BioCryst Pharma (BCRX) PT Raised to $27 at Citizens on Navenibart Deal, Strong HAE Fit
Oct 14, 2025 04:34PM Oppenheimer Downgrades Astria Therapeutics (ATXS) to Perform
Oct 14, 2025 03:47PM BioCryst Pharma (BCRX) PT Raised to $15 at RBC Capital Amid 10pct Decline
Oct 14, 2025 03:04PM BioCryst Pharma (BCRX) PT Raised to $15 at Jefferies
Oct 14, 2025 06:55AM BioCryst Pharma (BCRX) Halted, News Pending
Oct 1, 2025 06:36AM Evercore ISI Downgrades BioCryst Pharma (BCRX) to In Line
Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
Aug 11, 2025 07:02AM BioCryst chief research officer to depart September 1
Aug 4, 2025 07:01AM BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance
Jul 24, 2025 12:20PM RBC Capital on BioCryst Pharma (BCRX): 'We See Shares Undervalued'
Jul 7, 2025 07:01AM BioCryst (BCRX) names Babar Ghias as CFO and head of corporate development
Jun 27, 2025 07:01AM BioCryst Pharma (BCRX) Announces Sale of European ORLADEYO Business to Neopharmed Gentili for up to $264 Million
Jun 16, 2025 07:02AM BioCryst Pharma (BCRX) Presents New Data on the Long-term Efficacy and Safety of ORLADEYO
Jun 13, 2025 07:00AM BioCryst Pharma (BCRX): ORLADEYO Approved in Colombia
Jun 6, 2025 07:00AM BioCryst Pharma (BCRX) Achieves Reimbursement for ORLADEYO Across all Major European Countries
May 30, 2025 07:01AM BioCryst Pharma (BCRX) Highlights Real-world Data Showing ORLADEYO Consistently Reduces HAE Attacks Across All Ages
May 16, 2025 07:01AM BioCryst Pharma (BCRX) Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO
May 6, 2025 09:43AM BioCryst Pharma (BCRX) PT Raised to $13 at RBC Capital; 'Strong Out of the Gate in 2025'
May 5, 2025 04:08PM BioCryst Pharma (BCRX) PT Raised to $14 at Jefferies
May 5, 2025 07:02AM BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance
May 1, 2025 07:02AM BioCryst Pharma (BCRX) Appoints Steve Frank to its Board
Apr 29, 2025 06:35AM Cantor Fitzgerald Starts BioCryst Pharma (BCRX) at Overweight
Apr 23, 2025 04:17AM Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Mar 3, 2025 04:34AM Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
Feb 25, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)
Feb 25, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
Feb 24, 2025 01:18PM Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
Feb 24, 2025 08:58AM JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)
Feb 24, 2025 07:29AM BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook
Feb 18, 2025 04:13AM JMP Securities Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
Feb 12, 2025 07:01AM BioCryst Pharma (BCRX) Launches ORLADEYO in Portugal
Feb 10, 2025 08:33AM BioCryst Pharma (BCRX) to Present New ORLADEYO Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
Feb 5, 2025 03:29PM BioCryst Pharma (BCRX) 5,200 contracts of January 10 calls trade
Jan 31, 2025 05:10AM JMP Securities Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
Jan 10, 2025 02:29PM BioCryst Pharma (BCRX) PT Raised to $12 at Evercore ISI
View Older Stories